Latest news with #Cytokinetics
Yahoo
2 days ago
- Business
- Yahoo
Citi Lowers Cytokinetics (CYTK) PT to $77 Due to Uneventful Q2 2025 Earnings
Cytokinetics Incorporated (NASDAQ:CYTK) is one of the best upside stocks to invest in now. On August 8, Citi lowered the firm's price target on Cytokinetics to $77 from $80, while keeping a Buy rating on the shares. This sentiment followed the company's Q2 2025 earnings report, which the firm views as uneventful. In Q2, Cytokinetics reported a net loss of $134.4 million, or $1.12 per share, which was an improvement from the net loss of $143.3 million, or $1.31 per share, reported in Q2 2024. Cytokinetics ended the quarter with ~$1.04 billion in cash and investments, which was a decrease from the $1.09 billion reported at the end of Q1 2025. A lab technician using a microscope to examine the biopharmaceutical company's molecules. In terms of clinical development, the FDA extended the PDUFA date for Aficamten to December 26, which may delay the drug's approval and launch timeline. However, the company noted that all Good Clinical Practice/GCP inspections for Aficamten were completed with no negative observations, which is a positive sign for the regulatory process. The company is preparing for a late-cycle meeting with the FDA in September, which is scheduled to align with the PDUFA date extension. Cytokinetics Incorporated (NASDAQ:CYTK) is a late-stage biopharmaceutical company that discovers, develops, and commercializes muscle activators and inhibitors as potential treatments for debilitating diseases in the US. While we acknowledge the potential of CYTK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
07-07-2025
- Business
- Yahoo
Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Cytokinetics, Incorporated (NASDAQ:CYTK) on June 4 and set a price target of $107.00. A lab technician using a microscope to examine the biopharmaceutical company's molecules. JPMorgan analyst Tessa Romero also gave Cytokinetics, Incorporated (NASDAQ:CYTK) a rating update on June 9, lowering the firm's price target to $53 from $71 while keeping an Overweight rating on the shares. The firm stated that it updated its revenue forecasts for aficamten following recent management commentary that the launch of Camzyos is a realistic cadence for an obstructive hypertrophic cardiomyopathy launch. It added that the deciding factor for the attitude of investors and physicians towards the drug's potential adoption would be the label. The firm believes that aficamten is a 'really good drug' to treat obstructive hypertrophic cardiomyopathy, boasting a differentiated profile compared to Camzyos. This holds especially true when considering dosing, safety, and pharmacology. It thus contended that the data to date supports approval. Cytokinetics, Incorporated (NASDAQ:CYTK) is a biopharmaceutical company that discovers, develops, and commercializes muscle inhibitors to treat diseases that affect muscle performance. It develops small-molecule drug candidates, particularly engineered to affect muscle function and contractility. Its clinical-stage drug candidate portfolio includes omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. While we acknowledge the potential of CYTK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-06-2025
- Business
- Yahoo
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Biotech Stocks with Huge Upside Potential. Tessa Romero, an analyst at JPMorgan, has maintained her Overweight rating on Cytokinetics, Incorporated (NASDAQ:CYTK) but reduced the firm's price objective from $71 to $53. A lab technician using a microscope to examine the biopharmaceutical company's molecules. Aficamten's revised revenue projections, which anticipate a slower launch trajectory, are the basis for the modification. The management's latest remarks, which reflect the Camzyos launch pace for obstructive hypertrophic cardiomyopathy (oHCM), are consistent with this reevaluation. According to JPMorgan, expectations for adoption will be significantly influenced by the final medicine label. Cytokinetics, Incorporated (NASDAQ:CYTK) experimental treatment for oHCM, Aficamten, is still a valuable tool with promising clinical outcomes. Although JPMorgan admits that the launch trajectory was slower than anticipated, the company is still confident in the drug's unique profile when compared to Camzyos, especially with regard to pharmacology, safety, and dosing flexibility. These qualities and corroborating evidence support JPMorgan's assessment of aficamten's acceptability. The lower price objective is not a reflection of a shift in opinion about the drug's strategic worth or efficacy, but rather of modified commercial ramp assumptions. It is a late-stage biopharmaceutical business that focuses on discovering, developing, and bringing to market first-in-class muscle activators and next-in-class muscle inhibitors as possible cures for fatal diseases where muscle function is impaired or deteriorating. While we acknowledge the potential of CYTK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
10-06-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Addus Homecare (ADUS) and Cytokinetics (CYTK)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on QuidelOrtho (QDEL – Research Report), Addus Homecare (ADUS – Research Report) and Cytokinetics (CYTK – Research Report) with bullish sentiments. Confident Investing Starts Here: QuidelOrtho (QDEL) In a report issued on June 5, Conor McNamara from RBC Capital maintained a Buy rating on QuidelOrtho, with a price target of $60.00. The company's shares closed last Monday at $30.21, close to its 52-week low of $29.74. According to McNamara is ranked 0 out of 5 stars with an average return of -22.5% and a 18.4% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and SOPHiA GENETICS. QuidelOrtho has an analyst consensus of Moderate Buy, with a price target consensus of $45.00, which is a 48.4% upside from current levels. In a report issued on June 5, Craig-Hallum also maintained a Buy rating on the stock with a $60.00 price target. Addus Homecare (ADUS) In a report released yesterday, Ryan Daniels from William Blair maintained a Buy rating on Addus Homecare. The company's shares closed last Monday at $116.56. According to Daniels is a 4-star analyst with an average return of 8.4% and a 49.6% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Pediatrix Medical Group, and Lifestance Health Group. Addus Homecare has an analyst consensus of Strong Buy, with a price target consensus of $135.17, representing a 18.7% upside. In a report issued on June 1, Jefferies also maintained a Buy rating on the stock with a $160.00 price target. Cytokinetics (CYTK) In a report issued on June 5, Leonid Timashev from RBC Capital maintained a Buy rating on Cytokinetics, with a price target of $80.00. The company's shares closed last Monday at $33.13. According to Timashev is a 3-star analyst with an average return of 2.9% and a 42.7% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Perspective Therapeutics, and Edgewise Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics with a $75.21 average price target, a 128.3% upside from current levels. In a report issued on May 26, Stifel Nicolaus also maintained a Buy rating on the stock with a $87.00 price target.
Yahoo
05-06-2025
- Business
- Yahoo
Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Cytokinetics (CYTK). Shares have lost about 1.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Cytokinetics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. It turns out, fresh estimates have trended upward during the past month. The consensus estimate has shifted 8.98% due to these changes. At this time, Cytokinetics has a poor Growth Score of F, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy. Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Cytokinetics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. Cytokinetics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Vertex Pharmaceuticals (VRTX), has gained 2.5% over the past month. More than a month has passed since the company reported results for the quarter ended March 2025. Vertex reported revenues of $2.77 billion in the last reported quarter, representing a year-over-year change of +3%. EPS of $4.06 for the same period compares with $4.76 a year ago. Vertex is expected to post earnings of $4.24 per share for the current quarter, representing a year-over-year change of +133.1%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.3%. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Vertex. Also, the stock has a VGM Score of C. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cytokinetics, Incorporated (CYTK) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
